Market Currents

• Wednesday, November 11, 2009

• 09:42 AM Sanofi-Aventis (SNY +0.1%) increases its 2007 biotech deal with Regeneron Pharmaceuticals (REGN +15.1%), boosting its payment for R&D to $160M/year from $100M, and extending the pact by five years, through 2017. REGN chief Dr. Leonard S. Schleifer says the deal is a model of how Big Pharma can collaborate with biotech without suffocating it: "They leave Regeneron and its culture to do its thing." (PR) Comment!

• Thursday, July 23, 2009

• 15:39 PM After Medarex (MEDX +89%) fetched a healthy premium from Bristol-Myers Squibb (BMY +3.1%), investors have begun looking at similar companies to see who's next up for bids: Regeneron Pharmaceuticals (REGN +8.8%)? Seattle Genetics (SGEN +5.6%)? Alexion (ALXN +7.6%)? Allos Therapeutics (ALTH +6.9%)? Celldex Therapeutics (CLDX +6.7%)? Dendreon (DNDN +6.6%)? Comment!